<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Brady</id>
	<title>Brady - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Brady"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Brady&amp;action=history"/>
	<updated>2026-10-05T18:11:37Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Brady&amp;diff=37&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Brady&amp;diff=37&amp;oldid=prev"/>
		<updated>2016-07-14T02:15:44Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''Hyperbaric oxygenation and a smaller number of fractions for irradiation was not associated with improved survival or local recurrence rate in carcinoma of the cervix.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. No evidence of a benefit with smaller number of fractions and hyperbaric oxygen with regard to survival or local recurrence rates. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. A trend to improved local control rate in those actually receiving hyperbaric oxygen was not statistically significant. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. There was also a trend in the oxygen group to a greater risk of treatment complications. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Mike Bennett, Dept of Diving and Hyperbaric Medicine, Prince of Wales Hospital, Sydney; Friday, 19 February 1999 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient with carcinoma of the cervix presented for radiotherapy. We wondered if irradiation while having hyperbaric oxygen would result in improved tumour control or survival. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Question:''' In patients with carcinoma of the cervix who present for radiotherapy, does the conduct of radiotherapy while in hyperbaric oxygen, compared to irradiation in air, result in any improvement in local or distant tumour control, or survival? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, tumour/cervix &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Non-blinded randomised controlled trial without intention-to-treat. Patients with stage IIB to IVA cervical cancer presenting for radiotherapy at one of four treatment centres. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Control group (N = 29; 29 analysed): 5,000 rads total dose over 5 weeks with 25 fractions (1,530 rets) in air. Intracavitary irradiation where possible. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Experimental group (N = 29; 29 analysed): 4,000 rads over 5 weeks with 10 fractions (1,524 rets) in oxygen at 3ATA for up to 45 minutes. Intracavitary irradiation where possible. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
{| &lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Time to Outcome''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Air group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''HBO group''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Relative risk increase''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Absolute risk increase''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''NNH''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Death''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 years &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.59 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.62 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;5% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.03 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;33 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-38% to 48% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.22 to 0.28 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNH'''4 to INF NNT'''5 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Local recurrence''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 years &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.276 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.345 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;25% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.07 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-14 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;61% to 100% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.17 to 0.31 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNH'''3 to INF NNT'''6 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''Treatment complications and no tumour''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;4 years &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.069 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.172 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;149% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;0.10 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-10 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
| &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;'''95% CI:''' &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; ||   ||   ||   || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-91% to ?% &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;-0.06 to 0.27 &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; || &amp;lt;span style'''&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&amp;lt;span style'''&amp;quot;display: block; font-family: arial,helvetica,sans-serif; font-size: 110%; text-align: center;&amp;quot;&amp;gt;NNH'''4 to INF NNT'''16 to INF &amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt; &lt;br /&gt;
|-&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Small trial in which 10/29 patients randomised to hyperbaric oxygen did not receive it. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Trends to lower rate of local recurrence and higher rate of treatment complications in the hyperbaric oxygen group when not analysed by intention to treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:''' January 2004 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' 1.Brady LW, Plenk HP, Hanley JA, Glassburn JR, Kramer S, Parker RG. Hyperbaric oxygen therapy for carcinoma of the cervix- stages IIB, IIIA, IIIB and IVA: results of a randomised study by the radiation therapy oncology group. International Journal of Radiation Oncology, Biology and Physics 1981;7:991-998.&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;display: block; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
[[File:sumhorsa.gif|center|sumhorsa.gif]]&lt;br /&gt;
&amp;lt;span style=&amp;quot;background-color: #ffffff; display: block; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: Arial,Helvetica,sans-serif; font-size: 26px; text-align: center;&amp;quot;&amp;gt;[[DXRTpelvis  |  BACK]]&amp;lt;/span&amp;gt;&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>